Concourse Financial Group Securities, Inc. Viking Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 700 shares of VKTX stock, worth $46,109. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 600
16.67%
Holding current value
$46,109
Previous $31,000
41.94%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding VKTX
# of Institutions
478Shares Held
66.1MCall Options Held
6.24MPut Options Held
3.01M-
Vanguard Group Inc Valley Forge, PA10.1MShares$665 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$397 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$337 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$148 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$122 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...